GlassScriptPhysician profile
Son B Nguyen
NPI 1710121348
$5,578.96
in general payments reported to CMS, 2019-2025
36 companies · $745 in 2025
The $745 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $757 · 2021: $710 · 2022: $934 · 2023: $754 · 2024: $725 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,224.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $859.13 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $716.68 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $707.14 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $558.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $465.60 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Gilead Sciences, INC. | $444.05 | 2019-2025 | |
| Pfizer INC. | $274.75 | 2019-2024 | |
| Amgen INC. | $172.80 | 2023-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $168.21 | 2019-2021 | |
| Vbi Vaccine (Delaware) INC. | $149.52 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $135.14 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $103.75 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $92.48 | 2019-2022 | |
| Exact Sciences Corporation | $67.41 | 2023-2025 | Cologuard Collection Kit |
| Indivior INC. | $66.98 | 2023-2025 | Sublocade |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $64.64 | 2020-2024 | |
| Allergan, INC. | $59.87 | 2019-2020 | |
| Amarin Pharma, INC. | $48.33 | 2020 | |
| Seqirus USA INC | $46.86 | 2021-2025 | Fluad, Flucelvax |
| Orexo US, INC. | $46.54 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.92 | 2022 | |
| Dynavax Technologies Corporation | $36.95 | 2019 | |
| Esperion Therapeutics, INC. | $32.06 | 2021 | |
| Genentech USA, INC. | $28.04 | 2019 | |
| Astellas Pharma US INC | $23.25 | 2023 | Myrbetriq |
| Kestra Medical Technology Services, INC. | $22.50 | 2025 | Assure Wcd |
| Alkermes, INC. | $20.60 | 2022 | |
| Shield Therapeutics INC | $18.99 | 2025 | |
| Inspire Medical Systems, INC. | $17.04 | 2023 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $15.29 | 2020 | |
| Sanofi Pasteur INC. | $14.11 | 2024 | |
| Avion Pharmaceuticals | $13.65 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.09 | 2024 | Zoryve |
| Janssen Pharmaceuticals, INC | $12.09 | 2021 | |
| Boston Scientific Corporation | $11.94 | 2021 | |
| Qiagen, LLC | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Son Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.